AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06802081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Weekly subcutaneous injections starting with dose 2.5mg, then increase dose by 2.5mg at week 4 (5mg), week 8 (7.5mg) and at week12 (10mg) as tolerated.
Study NCT06802081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Weekly subcutaneous injections starting with dose 2.5mg, then increase dose by 2.5mg at week 4 (5mg), week 8 (7.5mg) and at week 12 (10mg).
Study NCT06800781 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prolonged treatment with posterior pericardial chest tube plus standard care
Description: Prolonged treatment with posterior pericardial chest tube plus standard care All patients will receive chest tubes based on each surgeon's preference. Usually, 1 or 2 tubes are inserted in the mediastinum, and 1 is inserted into each open pleural cavity. Patients in the intervention arm will receive an additional posterior 20Ch chest tube. In cases where the surgeon routinely inserts 2 mediastinal chest tubes, they will use 1-2 anterior mediastinal tubes in the intervention group, based on their preference. The posterior chest tube will be positioned between the inferior aspect of the heart and the pericardium and connected to an active suction system per routine. Once the remaining chest tubes are extracted, the posterior chest tube will remain positioned in the pericardium and be reconnected from active suction to a collection bag for passive drainage. The chest tube will be removed on postoperative Day 3 or when chest tube output is \<50 mL/24 h.
Study NCT06800495 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THALEA (Thalassemia Education and Awareness) Kit
Description: By using the opinions obtained by the experts, THALEA's content will then be designed using the Theory of Planned Behaviour (TPB) by Ajzen and Fishbein.~Development of THALEA:~• Language: Malay and English.~• Contents of the THALEA kit: i. PowerPoint or Canva presentations with discussion prompts (softcopy form) ii. Links/joining codes to free educational game platforms such as Kahoot or Quizziz iii. Videos - convey messages on thalassemia awareness and screening importance.~iv. Illustrated guides/brochures - to provide step-by-step tutorials on how to get thalassemia screening in both the public and private healthcare.~• Developer would be the main researcher with aid from: i. Illustrator ii. Video graphic designer iii. Influencers~• Delivery of THALEA to students by: i. Medical personnel
Study NCT06800495 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic thalassemia and family health education
Description: They are basic family health education in which it is the usual family health education given by the MOH, usually delivered by a medical officer, to fourth form students at government schools prior to the thalassemia screening programme. It will consist of a delivery of a PowerPoint presentation and videos, that will be obtained from government public health clinics in Klang Valley.
Study NCT06801795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AviClear
Description: Participants will receive as many as 4 treatments, each treatment lasts approximately 10 minutes, with intervals of up to 5 weeks apart. The treatments will be conducted in person. Participants will be followed at approximately week 5 post-treatment completion (via phone) at 12 weeks and 24 weeks post treatment completion onsite.~This is a 1726 nanometer laser treatment
Study NCT06800690 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary Estrogen Level
Description: Women had urinary estrogen metabolite levels measured daily to identify both the nadir (menstruation) and the peak (peri-ovulation) of the cycle. Men were also tested at the same time intervals, approximately two-weeks apart.
Study NCT06801938 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perioperative Cystoscopy and Methylene Blue Test
Description: The ability of perioperative methylene blue and cystoscopy versus postoperative cystoscopy to detect complications will be compared in patients.
Study NCT05320874 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KM257 Bispecific antibody
Description: Part 1a dose escalation:~There will be 3 increasing dose levels (3mg/kg,6mg/kg,12mg/kg). Patients will be intravenously administrated with one dose of KM257, QW for continuous cycles of 21 consecutive days for each cycle. The dosing interval may be adjusted during the study based on emerging data from this trial.~Part 1b dose expansion:~Part1b:For cohort 1 and cohort2, KM257 will be given at the RP2D identified in Part1a;~For cohort 3 to 7:KM257 will be given combined with one of the following selected drug combination:~Drug: Capecitabine Combination therapy with KM257 - Cohort 3~Drug: Paclitaxel or Docetaxel or Irinotecan Combination therapy with KM257 - Cohort 4~Drug: Gemcitabine+Cisplatin Combination therapy with KM257 - Cohort 5~Drug: Gemcitabine+Cisplatin or Carboplatin Combination therapy with KM257 - Cohort 6~Drug:Carboplatin+Paclitaxel Combination therapy with KM257 - Cohort 7
Study NCT05985200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3032950
Description: BI 3032950
Study NCT06800950 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV
Description: Quadrivalent Influenza Virus Split Vaccine containing H1N1, H3N2, Bv, By antigens of 0.5ml for each dose
Study NCT06800950 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: QIV Control
Description: Quadrivalent Influenza Virus Split Vaccine containing each type of antigens of 0.5ml for each dose
Study NCT06800313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLD-0915
Description: A treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)
Study NCT06800924 — intervention group
Intervention type: OTHER
Intervention: Postural and mobility analysis
Description: Postural and mobility parameters were obtained with the use of the Idiag M360 scan tool (Idiag, Fehraltorf, Switzerland)
Study NCT05263037 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EaseVRx
Description: VR software with interactive content
Study NCT05263037 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham VR
Description: VR with neutral non-interactive content
Study NCT05985200 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BI 3032950
Description: Placebo matching BI 3032950
Study NCT04693897 — intervention group
Intervention type: DRUG
Intervention: Mirabegron 50 MG
Description: Mirabegron 50mg once daily given to treatment in patients with overactive bladder syndrome
Study NCT05286658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MEG/EEG
Description: The participant will sit still while their head is slid into the helmet-shaped bottom of the MEG device. The MEG contains sensors that passively detect weak magnetic fields outside the head produced by brain activity. The computer records the brain's electrical activity on the screen as wavy lines. The investigators will also ask you to wear sensors to capture eye-blinks (electrooculogram) and heartbeats (electrocardiogram) to facilitate removal from the MEG signal during analysis.~Participant will sit in front of a projector screen and be asked to put on a pair of headphones. Participant will be shown real words or nonsense words to read, the investigators may play sounds through headphones for the participant to repeat. Participant speech will be recorded by a microphone. The investigators may ask the participant to identify what they heard by pressing a button on a button-box. These tasks are expected to take about one hour to complete.
Study NCT05286658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MRI
Description: An MRI is a test that uses a magnetic field and pulses of radio wave energy to make pictures of organs and structures inside the body. The participant will be able to hear and speak to the research staff at all times during the MRI procedures. The MRI test will take about 15 minutes.
Study NCT05286658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speaking Tasks
Description: The participant may be asked to perform some of the tasks from MEG again, this time outside of the scanner. As before, the participant may see real words or nonsense words to read, and the investigators may play sounds through headphones and ask the participant to repeat them. Participant speech will be recorded by a microphone. The investigators may ask the participant to identify what they heard by pressing a button on a button-box. These tasks are expected to take about one hour to complete.
Study NCT06362330 — intervention group
Intervention type: OTHER
Intervention: magnetic resonance imaging
Description: Patients of bladder cancer underwent multiparameter magnetic resonance imaging before surgery
Study NCT05091697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent treatment VIRTUAL FIBROWALK + TAU
Description: To assess the effectiveness and cost-utility of the virtual multicomponent program (Fibrowalk)
Study NCT06429436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VENDY
Description: At least 1 machine (vending machine like a snack machine or a machine like a newspaper kiosk) will be placed in the respective community served by the participating organizations. Any person in the community can get naloxone from the machine. The vending machine will require a code that will be placed on the machine for anyone to use. The kiosks are a box that you simply pull open and naloxone can be obtained. Naloxone kits will be provided for free as part of the current naloxone distribution program within each respective organization.
Study NCT06801613 — intervention group
Intervention type: OTHER
Intervention: Intervention Group
Description: Group/Cohort Description: Participants with Upper Cross Syndrome (UCS) who undergo the prescribed exercise or treatment protocol.
Study NCT06800703 — intervention group
Intervention type: BEHAVIORAL
Intervention: follow up interviews for 12 months to determine opioid use
Description: Follow-up
Study NCT06800664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health providers and management at IG sites will receive ISS (i.e., management support, capacity-building, and social network support) and training on the HOPE implementation plan
Description: Health providers and management at IG sites will receive ISS (i.e., management support, capacity-building, and social network support) and training on the HOPE implementation plan
Study NCT06800664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Providers in the control group will not receive ISS support
Study NCT05139121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR-100A-01
Description: Transdermal contraceptive delivery system
Study NCT06801002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JBZ-001
Description: JBZ-001 Oral Capsule
Study NCT05091697 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multicomponent treatment VIRTUAL FIBROWALK + TAU
Description: To assess the effectiveness and cost-utility of the virtual multicomponent program (Fibrowalk)
Study NCT06010758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Listerine Experimental Mouthwash
Description: After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Experimental Mouthwash twice a day, morning and night.
Study NCT04693897 — intervention group
Intervention type: DRUG
Intervention: Solifenacin Succinate 5 MG
Description: Solifenacin 5mg once daily given to treatment in patients with overactive bladder syndrome
Study NCT06587919 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurofeedback
Description: EEG-based neurofeedback, administered with the Neuroguide software.
Study NCT06587919 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Neurofeedback
Description: EEG-based neurofeedback, administered with the Neuroguide software.
Study NCT05147324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyPlan - Individualized Planned Eating Pattern
Description: Sessions involve a structured behavior change counseling module derived from FLEX (NCT01286350), DASH-4-Teens (NCT00585832), and a Social Cognitive Theory and Transtheoretical Model informed conceptual framework, which uses education, motivation and self-efficacy enhancement, goal setting, and problem-solving skills training to initiate and sustain eating pattern adherence. Sessions support incremental progress towards meeting all five eating behavior goals by helping youth develop action plans, troubleshoot barriers to adherence, and refine action plans to improve adherence. Youth log in MyFitnessPal at least three days per week. Logs are used to assess and troubleshoot adherence, support youth in developing and refining action plans, and reward youth with points. Incentives are allocated using a point scheme designed to promote logging and goal achievement. Formal adjustment of the eating pattern is based on adherence according to logs and youth/guardian acceptability.
Study NCT04995588 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood test
Description: Unique blood draw of 45mL for all the participants
Study NCT06596564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: choice architecture
Description: Display the sugar content of the drink on the platform.
Study NCT06596564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: choice architecture
Description: Showing the various harms that can come from long-term excessive consumption of sugary beverages on the platform.
Study NCT06596564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: choice architecture
Description: The platform shows the information that the majority of their peers have chosen mineral water.
Study NCT06207604 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open sinus lifting without bone grafting and simultaneous implant placement
Description: no bone graft will be used after open sinus lifting
Study NCT06207604 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open sinus lifting with bone grafting and simultaneous implant placement
Description: bone graft will be packed palatally after open sinus elevation and before implant placement, then implant placement will took place followed by packing of bone grafts
Study NCT06612840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNC-077
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study NCT04865172 — intervention group
Intervention type: OTHER
Intervention: Remote collection of passive and active data for 28 consecutive days
Description: Passive sensor data: collected continuously for 28 days, from a multi-sensor wearable bracelet worn by each member of the dyad; Active questionnaire data: collected once a week during the four weeks of monitoring (and at the end of the 28 days for patient-caregiver dyads), from questionnaires filled by one partner of the dyad (for patient-caregiver dyads, this will be the caregiver) using a smartphone application.
Study NCT06668623 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reiki Group
Description: Remote Reiki application will be performed once a day for 20 minutes for four days by a researcher who has received second level training. No changes will be made to the standard treatment plan of the patients during the application.
Study NCT06668623 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Reiki Group
Description: In the placebo group, the Sham Reiki group will receive remote Reiki application in accordance with the application protocol by a nurse who is not a Reiki practitioner trained by the researcher and has not received any previous training.
Study NCT06010758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will brush twice daily for 1 timed minute with Colgate Cavity Protection toothpaste.
Study NCT06010758 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will brush twice daily for 1 timed minute with Colgate Cavity Protection toothpaste.
Study NCT06010758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Listerine Total Care Zero
Description: After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Total Care Zero mouthwash twice a day, morning and night.
Study NCT06010758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listerine Cool Mint Zero
Description: After brushing for 1 timed minute, participants will rinse full strength for 30 seconds with Listerine Cool Mint Zero mouthwash twice a day, morning and night.
Study NCT06678269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: The dose escalation portion of the study, a 3+3 design will be used. Once the MTD of Abemaciclib is reached, the phase Ib expansion portion will enroll up to 10 additional patients also requiring palliation to bone metastases
Study NCT06621771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music intervention
Description: Participants will engage in a step-by-step piano training consisting in playing piano pieces designed to involve all 5 digits of the paretic hand and increasing in complexity. They will be using a Musical Instrument Digital Interface (MIDI) piano program called Synthesia to display musical pieces on a computer screen that is adapted for people with no music reading abilities and will be playing on a touch sensitive piano keyboard. The supervised session will also be complemented with a unsupervised home program consisting of piano sequence exercises comprising short excerpts of the same musical pieces practiced during the supervised sessions and they will receive a roll-up flexible piano
Study NCT06621771 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational Therapy
Description: Participants will receive conventional occupational therapy treatment (e.g., mobility, ADL, IALD, information session), excluding treatments focusing specifically on arm and hand motor recovery.The supervised session will also be complemented with an unsupervised home program consisting of assignments related to occupational therapy exercises and/or IALD/ADLs.
Study NCT06696690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MNS
Description: The MNS treatment group use the NeuroTrac™ Multi-TENS transcutaneous electrical stimulator to provide an asymmetric biphasic pulse train with a frequency of 35 Hz, an amplitude of 20 mA and a pulse width of 300 ms, which is on for 20 seconds and off for 50 seconds. The treatment lasts for 8 hours per day and the treatment course lasts for one week.
Study NCT06696690 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham stimulation
Description: The sham stimulation treatment group utilized the same stimulation device and was subjected to a safe yet ineffective stimulation protocol for sham stimulation. The treatment lasts for 8 hours per day and the treatment course lasts for 14 days.
Study NCT06699693 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasonography-guided PENG block
Description: This study aimed to evaluate the effect of ultrasonography-guided PENG block prior to joint mobilization therapy on shoulder pain, function, and kinesiophobia in patients with AC resistant to conservative treatment, in comparison with a control group
Study NCT06699693 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization
Description: The mobilization methods encompassed the scapula and clavicular joints, in addition to the glenohumeral (GH) joint, taking into consideration their biomechanical interactions. These exercises were supervised and administered by the physiotherapist during each session. Additionally, the patients were provided with a home exercise program that included exercises for posture, thera band, and finger ladder, with instructions to perform 10-15 repetitions twice a day independently \[
Study NCT06698783 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortimel
Description: In this study, patients will be provided with ONS preparation (4 kinds of ready-to-drink special medical food) free of charge during the treatment period. Doctors will provide patients with different flavor nutritional preparations on a weekly basis, 2 bottles per day for patients with 1 flavor per week, and 14 bottles per day for each of 4 flavors at the recommended dosage of 400 kcal per day 28 days
Study NCT06699784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive lenses intervention
Description: Progressive lenses intervention group will receive 1-month progressive lens correction in daily life.
Study NCT06699784 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Single-vision lenses intervention
Description: Single-vision lenses intervention group will use near-vision spectacles during near work and use their original habitual distant glasses for distance tasks for 1 month.
Study NCT06699316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized prognostic counselling
Description: Individualized prognostic counselling on life expectancy using the prognostic model 'OncologIQ Palliative'
Study NCT06699576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20093
Description: HS-20093: administered as an IV infusion
Study NCT04945278 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Double mirror device ALTER-EGO
Description: The patient and his matched healthy volunteer will be placed on each side of the double mirror device ALTER-EGO. Both sides will be lightened alternatively or at the same time by lights, so according to the light intensity, the subject will see himself in a mirror or the other person throw a classic window. The light intensity will vary from 0 to 100% and to 100% to 0% alternatively from each side of the mirror. At each 10% variation of one side, both patient and volunteer will have to answer that question : who do you see more : him/her or yourself ?